Monogram Orthopaedics, Inc.

NasdaqCM MGRM

Monogram Orthopaedics, Inc. EBIT Margin for the Trailing 12 Months (TTM) ending September 30, 2024: -4,456.87%

Monogram Orthopaedics, Inc. EBIT Margin is -4,456.87% for the Trailing 12 Months (TTM) ending September 30, 2024. EBIT ratio is the ratio of EBIT to revenue, measuring a company's operating profitability without considering non-operating income or expenses.
  • Monogram Orthopaedics, Inc. EBIT Margin for the Trailing 12 Months (TTM) ending September 30, 2022 was -561,244.44%, a -40,149.31% change year over year.
  • Monogram Orthopaedics, Inc. EBIT Margin for the Trailing 12 Months (TTM) ending September 30, 2021 was -1,394.42%.
Key data
Date EBIT Margin EPS (Basic) EPS (Diluted) Shares (Basic, Weighted)
Market news
Loading...
NasdaqCM: MGRM

Monogram Orthopaedics, Inc.

CEO Mr. Benjamin Sexson C.F.A.
IPO Date May 18, 2023
Location United States
Headquarters 3913 Todd Lane
Employees 28
Sector Technology
Industries
Description

Monogram Orthopaedics, Inc. focuses on developing a product solution architecture to enable mass personalized optimization of orthopedic implants. The company intends to produce and market robotic surgical equipment and related software, orthopedic implants, tissue ablation tools, navigation consumables, and other miscellaneous instrumentation for use in reconstructive joint replacement procedures. Its robot prototype executes optimized paths for high-precision insertion of optimized implants in synthetic bone specimens. The company was formerly known as Monogram Arthroplasty Inc. and changed its name to Monogram Orthopaedics, Inc. in March 2017. The company was incorporated in 2016 and is headquartered in Austin, Texas.

StockViz Staff

January 15, 2025

Any question? Send us an email